These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21393063)

  • 21. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Charcot-Marie-Tooth disease and related inherited neuropathies.
    Murakami T; Garcia CA; Reiter LT; Lupski JR
    Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal models of Charcot-Marie-Tooth disease type 1A.
    Sereda MW; Nave KA
    Neuromolecular Med; 2006; 8(1-2):205-16. PubMed ID: 16775377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability of clinical outcome measures in Charcot-Marie-Tooth disease.
    Solari A; Laurà M; Salsano E; Radice D; Pareyson D;
    Neuromuscul Disord; 2008 Jan; 18(1):19-26. PubMed ID: 17964785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ
    Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.
    Mandarakas MR; Eichinger KJ; Bray P; Cornett KMD; Shy ME; Reilly MM; Ramdharry GM; Scherer SS; Pareyson D; Estilow T; McKay MJ; ; Herrmann DN; Burns J
    Neurology; 2024 Feb; 102(3):e207963. PubMed ID: 38237108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
    Mori L; Prada V; Signori A; Pareyson D; Piscosquito G; Padua L; Pazzaglia C; Fabrizi GM; Smania N; Picelli A; Schenone A;
    Eur J Phys Rehabil Med; 2019 Feb; 55(1):47-55. PubMed ID: 29898585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the Italian version of the Charcot-Marie-Tooth Health Index.
    Pisciotta C; Ciafaloni E; Zuccarino R; Calabrese D; Saveri P; Fenu S; Tramacere I; Genovese F; Dilek N; Johnson NE; Heatwole C; Herrmann DN; Pareyson D;
    J Peripher Nerv Syst; 2020 Sep; 25(3):292-296. PubMed ID: 32511835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.
    Cornett KM; Menezes MP; Bray P; Halaki M; Shy RR; Yum SW; Estilow T; Moroni I; Foscan M; Pagliano E; Pareyson D; Laurá M; Bhandari T; Muntoni F; Reilly MM; Finkel RS; Sowden J; Eichinger KJ; Herrmann DN; Shy ME; Burns J;
    JAMA Neurol; 2016 Jun; 73(6):645-51. PubMed ID: 27043305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic spectrum of Charcot-Marie-Tooth disease due to LITAF/SIMPLE mutations: a study of 18 patients.
    Guimarães-Costa R; Iancu Ferfoglia R; Leonard-Louis S; Ziegler F; Magy L; Fournier E; Dubourg O; Bouche P; Maisonobe T; Lacour A; Moerman A; Latour P; Stojkovic T
    Eur J Neurol; 2017 Mar; 24(3):530-538. PubMed ID: 28211240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A).
    Sereda MW; Meyer zu Hörste G; Suter U; Uzma N; Nave KA
    Nat Med; 2003 Dec; 9(12):1533-7. PubMed ID: 14608378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients.
    Tozza S; Bruzzese D; Pisciotta C; Iodice R; Esposito M; Dubbioso R; Ruggiero L; Topa A; Spina E; Santoro L; Manganelli F
    Eur J Neurol; 2018 Feb; 25(2):301-306. PubMed ID: 29053907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Charcot-Marie-Tooth disease].
    Lee YC; Chang MH; Lin KP
    Acta Neurol Taiwan; 2008 Sep; 17(3):203-13. PubMed ID: 18975529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
    Sahenk Z; Nagaraja HN; McCracken BS; King WM; Freimer ML; Cedarbaum JM; Mendell JR
    Neurology; 2005 Sep; 65(5):681-9. PubMed ID: 16157899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.